Rei Yokoyama
Minami, 7348553, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.
Journal: Biological & pharmaceutical bulletin
Published: June 28, 2026
Neuron-specific overexpression of human vasoactive intestinal peptide receptor 2 in mice causes cognitive dysfunction and abnormal dendritic morphology in the prefrontal cortex.
Journal: Journal of pharmacological sciences
Published: September 15, 2025
Recovery of centralities in medial prefrontal and sensory-related cortices associated with social behavior improvements in an autism mouse model.
Journal: Scientific reports
Published: December 19, 2024
Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gαi proteins, and to its functions in breast cancer cells.
Journal: British journal of pharmacology
Published: September 24, 2024
Brain region-specific neural activation by low-dose opioid promotes social behavior.
Journal: JCI insight
Published: April 29, 2024
Long-lasting anti-despair and anti-anhedonia effects of (S)-norketamine in social isolation-reared mice.
Journal: Journal of pharmacological sciences
Published: October 28, 2023
(R)-ketamine restores anterior insular cortex activity and cognitive deficits in social isolation-reared mice.
Journal: Molecular psychiatry
Published: August 29, 2023
Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites.
Journal: Neuropharmacology
Published: September 27, 2022
Claustrum mediates bidirectional and reversible control of stress-induced anxiety responses.
Journal: Science advances
Published: March 18, 2022
Altered Functional Connectivity of the Orbital Cortex and Striatum Associated with Catalepsy Induced by Dopamine D1 and D2 Antagonists.
Journal: Biological & pharmaceutical bulletin
Published: March 01, 2021
(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Journal: Pharmacology, biochemistry, and behavior
Published: January 28, 2020
Last Updated: 09/26/2026